We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04886388
Recruitment Status : Active, not recruiting
First Posted : May 14, 2021
Last Update Posted : January 18, 2022
Sponsor:
Information provided by (Responsible Party):
Better Therapeutics

Brief Summary:
BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control (i.e., levels of blood sugar). The BT-001 software delivers a type of behavioral therapy to patients via a mobile application that targets behaviors related to achieving glycemic control. The effectiveness of BT-001 will be measured by its ability to help patients reduce Hemoglobin A1c, or HbA1c (a marker in the blood that measures blood sugar) compared to standard medical care in patients with type 2 diabetes.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Device: BT-001 Other: Physician-guided Standard of Care for type 2 diabetes Phase 3

Detailed Description:

The study will utilize an open-label, randomized, parallel-group design to confirm and characterize the safety and efficacy of BT-001 used in addition to standard of care (SOC) when compared to SOC alone in patients with type 2 diabetes. The screening period will consist of a run-in during which time HbA1c will be assessed for confirmation of eligibility.

Once confirmed to be eligible, patients will then be randomized 1:1 to the following groups:

Investigational: One half of the participants will be treated with BT-001 plus SOC for 180 days;

Control: One half of the participants will be treated with SOC alone for 180 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 651 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Open-Label, Randomized, Controlled
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label, Randomized, Controlled, Parallel-Group Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes
Actual Study Start Date : April 22, 2021
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : November 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BT-001 + Standard of Care
BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes
Device: BT-001
BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.

Other: Physician-guided Standard of Care for type 2 diabetes
Current ADA Standard of Care Guidelines for type 2 diabetes

Active Comparator: Standard of Care
Patients randomized to the Standard of Care arm will receive Standard of Care treatment for type 2 diabetes under the guidance of a physician
Other: Physician-guided Standard of Care for type 2 diabetes
Current ADA Standard of Care Guidelines for type 2 diabetes




Primary Outcome Measures :
  1. The difference in the mean change from baseline in HbA1c at Day 90 between Intervention and Standard of Care groups [ Time Frame: Baseline and Day 90 ]
    Hemoglobin A1c (HbA1c) test measures the amount of blood sugar (glucose) attached to hemoglobin.


Secondary Outcome Measures :
  1. The difference in the mean change from baseline in HbA1c at Day 180 between Intervention and Standard of Care groups [ Time Frame: Baseline and Day 180 ]
    Hemoglobin A1c (HbA1c) test measures the amount of blood sugar (glucose) attached to hemoglobin.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Between 18 and 75 years old, inclusive at the time of signing the informed consent;
  2. Diagnosis of type 2 diabetes, according to the criteria of the American Diabetes Association (ADA), and confirmed at the initial eligibility screening;
  3. Body Mass Index ≥25 kg/m2;
  4. Possesses a smartphone (iPhone or Android only) capable of running the smartphone applications (Apps) used in the study;
  5. Has had no change in the last 4 months prior to randomization (3 months prior to initial screening plus 30-day run-in screening period) in antihyperglycemic medications;
  6. Has a current HbA1c level >7%, as determined by both screening assessments;
  7. Willing to use an FDA approved glucometer for self-monitoring blood glucose throughout the study;
  8. Is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).

Exclusion Criteria

  1. Are unable to understand, consent to, or comply with the study protocol for any reason;
  2. Currently taking prandial (mealtime) insulin;
  3. Have self-reported measures, collected during screening interview, that reveal:

    1. An active eating disorder
    2. The taking of or planning to take (within the next 6 months):

    i. Oral steroids (planned, or within the past 3 months) ii. Chemotherapy (planned, or within the past 6 months) iii. Weight loss medications or iv. Atypical antipsychotic medications

    c. A change in antidepressant or anti-anxiety medication within the past 3 months;

    d. A history of bariatric surgery or planned bariatric surgery during the study;

    e. The current use of marijuana, cocaine, opioid painkillers, or other addictive substances;

    f. The current use of tobacco products or use of tobacco products within the past 6 months;

    g. The consumption of alcohol above defined thresholds:

    i. For women: more than 3 drinks in a single day, or more than 7 drinks per week and ii. For men: more than 4 drinks in a single day, or more than 14 drinks per week

    h. An unstable or life-threatening medical illness;

    i. Non-resolved, presumed or confirmed COVID-19 diagnosis prior to randomization or during primary study period;

    j. For women only: pregnant (or lactating) or having the intention of becoming pregnant during the time frame of the study.

  4. Has a current HbA1c level ≥11%, at the screening assessment;
  5. Concurrent enrollment in any other clinical trial;
  6. Is considered unreliable by the investigator, or having any condition which, in the opinion of the investigator, would not allow safe participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04886388


Locations
Layout table for location information
United States, California
Study Site
San Francisco, California, United States, 94110
United States, Florida
Study Site
Miami, Florida, United States, 33101
United States, Georgia
Study Site
Atlanta, Georgia, United States, 30301
United States, Illinois
Study Site
Chicago, Illinois, United States, 60007
United States, New York
Study Site
New York, New York, United States, 10001
United States, Texas
Study Site
Houston, Texas, United States, 77001
Sponsors and Collaborators
Better Therapeutics
Investigators
Layout table for investigator information
Study Director: Mark Berman, MD Better Therapeutics
Additional Information:
Layout table for additonal information
Responsible Party: Better Therapeutics
ClinicalTrials.gov Identifier: NCT04886388    
Other Study ID Numbers: DM2-06
First Posted: May 14, 2021    Key Record Dates
Last Update Posted: January 18, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases